Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06717347 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 60 record versions are listed below. See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 275 → 278 locations
  2. Lead sponsor: Merck Sharp & Dohme LLC to Merck Sharp & Dohme LLC Trial sites expanded: 272 → 275 locations · Eligibility criteria expanded, about 24 words · Secondary endpoints: details revised at 8 of 10 entries Show 3 more changesShow less
    • Trial sites expanded: 272 → 275 locations
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 8 of 10 entries
  3. Study sites: 271 to 272v58
  4. Study sites: 270 to 271v57
  5. Study sites: 268 to 270v56
Show 13 earlier versionsHide 13 earlier versions
  1. Re-verified, no change to tracked fieldsv55
  2. Site details revised at 1 of 268 sitesv54
  3. Study sites: 267 to 268v53
  4. Site details revised at 2 of 267 sitesv52
  5. Study sites: 266 to 267v51
  6. Study sites: 264 to 266v50
  7. Study sites: 263 to 264v49
  8. Study sites: 264 to 263v48
  9. Study sites: 263 to 264v47
  10. Study sites: 262 to 263v46
  11. Study sites: 260 to 262v45
  12. Study sites: 258 to 260v44
  13. Study sites: 256 to 258v43
  1. Trial sites expanded: 253 → 256 locationsv42
  2. Study sites: 251 to 253v41
  3. Study sites: 250 to 251v40
  4. Study sites: 248 to 250 Interventions: Cyclophosphamide (Drug), Doxorubicin (Drug), Prednisolone (Drug), Prednisone (Drug), Rescue medication (Drug), Rituximab (Biological)… to Cyclophosphamide (Drug), Doxorubicin (Drug), Methylprednisolone (Drug), Prednisolone (Drug), Prednisone (Drug), Rescue medication (Drug)…v39 Show 1 more changeShow less
    • Interventions: Cyclophosphamide (Drug), Doxorubicin (Drug), Prednisolone (Drug), Prednisone (Drug), Rescue medication (Drug), Rituximab (Biological)… to Cyclophosphamide (Drug), Doxorubicin (Drug), Methylprednisolone (Drug), Prednisolone (Drug), Prednisone (Drug), Rescue medication (Drug)…
  5. Study sites: 247 to 248v38
  6. Study sites: 246 to 247v37
  7. Study sites: 242 to 246v36
  8. Site details revised at 1 of 242 sitesv35
  9. Study sites: 240 to 242v34
  10. Study sites: 238 to 240v33
  11. Study sites: 236 to 238v32
  12. Study sites: 235 to 236v31
  13. Study sites: 234 to 235v30
  14. Study sites: 233 to 234v29
  15. Study sites: 231 to 233v28
  16. Site details revised at 1 of 231 sitesv27
  17. Study sites: 228 to 231v26
  18. Site details revised at 1 of 228 sitesv25
  19. Study sites: 227 to 228v24
  20. Study sites: 224 to 227v23
  21. Study sites: 223 to 224v22
  22. Study sites: 220 to 223v21
  23. Study sites: 218 to 220v20
  24. Study sites: 216 to 218v19
  25. Study sites: 207 to 216v18
  26. Study sites: 199 to 207v17
  27. Study sites: 197 to 199v16
  28. Study sites: 196 to 197v15
  29. Study sites: 185 to 196v14
  30. Study sites: 180 to 185v13
  31. Study sites: 168 to 180v12
  32. Study sites: 123 to 168v11
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
DLBCL
650 trials monitored
See 38 trials at risk
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Trial Details
NCT Number NCT06717347
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Diffuse Large B-Cell Lymphoma
Enrollment 1,046 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov